Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 49-14 PENELOPE 

Phase III study evaluating palbociclib (PD-0332991), a CyclinDependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy.

DESIGN

please click on the picture to see a larger version

Study Chair
Dr. Marco Colleoni, EIO Milano, Italy

Statistician
Valentina Nekjudova, GBG Forschungs GmbH, Neu-Isenburg, Germany

Lead Trial Coordinator
Holly Shaw

Trial Monitors
Giuseppe Achille, Daniela Celotto, Carmen Comune

IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: PENELOPE-monitoring@ibcsg.org

Date of Activation

Targeted Accrual
800


News

14.06.2020:
Save the date and join the IBCSG Pink Ladies! June 14, 2020

20.03.2020:
The next IBCSG Annual Meeting will take place in Barcelona Spain on March 20 and 21, 2020.       

11.11.2019:
New publications are available 

All News

 
  Print